New research provides evidence that inhaling the psychedelic compound DMT, combined with psychological support, tends to reduce anxiety and improve life satisfaction in both healthy adults and individuals with depression. The findings suggest that the short-acting drug may foster long-term improvements in overall well-being and quality of life for people who do not respond to standard depression treatments. The study was published in the Journal of Psychopharmacology.
Psychedelic-assisted interventions are gaining attention for their potential to treat severe mental health conditions. Much of this research focuses on treatment-resistant depression. This condition is diagnosed when a patient does not experience relief after trying at least two different antidepressant medications.
Historically, mental health treatments have focused heavily on reducing negative symptoms. Contemporary frameworks suggest that full recovery also requires improvements in broader areas of well-being, such as life satisfaction, physical health, and social relationships. Existing literature indicates that classic psychedelics like psilocybin and ayahuasca can enhance these existential and social domains.
Dráulio Barros de Araújo, a professor of neuroscience at the Brain Institute of the Federal University of Rio Grande do Norte in Natal and director of the Center for Advanced Medical Psychedelics noted that the research team wanted to explore these wider outcomes. “Most clinical studies of psychedelics, including our previous work with ayahuasca and DMT, have focused primarily on changes in psychiatric symptoms, particularly depression,” Araújo said. “But recovery from depression is about much more than reducing a score on a depression scale.”
“Patients want to feel less anxious, function better in their daily lives, reconnect socially, and regain a sense of satisfaction, hope, and well-being,” Araújo said. “We therefore wanted to examine whether the effects we had previously observed with inhaled DMT extended to these broader dimensions of recovery.”
DMT, or N,N-dimethyltryptamine, offers a unique profile among psychedelics. When inhaled, it produces an intense but very brief altered state of consciousness lasting only five to twenty minutes. In contrast, substances like psilocybin or ayahuasca can cause effects lasting up to eight hours.
The short duration of inhaled DMT could make psychedelic therapies more accessible and less costly to administer in clinical settings. The authors designed their research to see if this brief experience could foster lasting changes in life satisfaction and quality of life.
The new paper is a secondary analysis of two separate but related open-label clinical trials. An open-label trial means that both the researchers and the participants knew what substance was being administered. Both groups received purified DMT vaporized in a clinical room designed for comfort and safety. Before receiving the drug, all participants underwent preparation sessions with a psychologist to build trust and discuss expectations.
The first trial involved 25 healthy volunteers with an average age of 30.3 years. These participants had previous experience with psychedelics. On the dosing day, they received two doses of DMT spaced a few hours apart. The researchers tested five different dosing schemes, starting with a lower dose followed by a higher dose to test safety and tolerance.
During the DMT experience, participants listened to specially composed music and later engaged in psychological integration sessions. To measure outcomes, the researchers had participants complete standardized questionnaires. They tracked state anxiety, which refers to how anxious a person feels in the present moment, on a four-point scale. They also measured life satisfaction on a seven-point scale and quality of life on a five-point scale.
The healthy volunteers reported reduced state anxiety immediately after the first dose. This reduction persisted for one day following the session. The statistical change for the initial anxiety drop was large, shifting nearly one full standard deviation below their baseline anxiety levels.
These healthy participants also reported increased life satisfaction that lasted up to 14 days post-administration. However, the healthy group did not show changes in quality of life. The researchers noted this might be due to a ceiling effect, meaning their baseline quality of life scores were already too high to show further mathematical improvement on the surveys.
The second trial focused on 14 patients with treatment-resistant depression. This group had an average age of 35.2 years and minimal prior experience with psychedelics. These patients received a fixed dosing schedule of 15 milligrams of DMT for the first session and 60 milligrams for the second session on the same day. Patients continued taking their regular psychiatric medications during the study to prevent clinical destabilization.
Like the healthy volunteers, the patients experienced drops in state anxiety that lasted up to one day after the DMT sessions. Early improvements in anxiety among these patients were also positively correlated with rapid decreases in self-reported depressive symptoms. The researchers looked closely at the magnitude of these initial changes across the participant group.
“Some of the observed effects were substantial,” Araújo told PsyPost. “In patients, the reduction in state anxiety immediately after the DMT session had a very large effect size, and improvements in life satisfaction, inner peace, and particularly hope and optimism were also large at the time points where significant differences were detected.”
“But effect sizes from a small, uncontrolled study should be interpreted cautiously,” Araújo said. “What I find particularly interesting is not only their magnitude, but the fact that the changes appeared across several dimensions of patients’ lives rather than being restricted to depressive symptoms.”
Beyond short-term anxiety relief, the patients reported enduring benefits over a longer period. They demonstrated increased life satisfaction at the 12-month mark compared to their baseline scores. The patients also reported sustained increases in physical, psychological, social, and environmental quality of life from 14 days up to 12 months.
When answering questions focused on spirituality and personal beliefs, the patients showed long-term enhancements in specific psychological areas. They reported improvements in feelings of inner peace at the 14-day mark. They also reported elevated levels of hope and optimism at both 14 days and 12 months after the sessions.
Araújo highlighted how unusual it is for a short-acting drug to be linked to such prolonged benefits. “The long-term findings were probably the most striking,” Araújo said. “DMT produces an extremely short psychedelic experience, generally lasting only several minutes, so observing improvements in some measures of quality of life as far as 12 months later is remarkable, especially when considering that patients were submitted to a single intervention with DMT.”
“We were also interested in seeing improvements in hope, optimism, and inner peace, because these dimensions are rarely considered primary outcomes in conventional antidepressant studies,” Araújo said. These distinct outcomes suggest a broader scope for evaluating mental health interventions.
“The main message is that the effects associated with DMT may extend beyond the reduction of depressive symptoms,” Araújo said. “In patients with treatment-resistant depression, we observed rapid reductions in anxiety and improvements in quality of life that were still detectable months later.”
“Life satisfaction was also significantly higher at the 12-month follow-up,” Araújo said. “Interestingly, some of the improvements involved very concrete aspects of quality of life, including physical and psychological health, social relationships, the environment, and hope and inner peace.”
The open-label design of both trials means that expectancy effects could have influenced the outcomes. Because participants knew they were receiving a powerful psychedelic, their anticipation of getting better might have artificially inflated their self-reported improvements. The lack of a placebo group prevents researchers from ruling out this possibility.
“At the same time, these findings should be considered preliminary,” Araújo said. “This was a small, open-label study without a placebo group, so we cannot conclude that DMT alone caused the long-term changes we observed.”
The intervention combined the pharmacological effects of DMT with extensive psychological support, music, and expressive exercises. It is not possible to separate the impact of the drug from the impact of the therapeutic environment. The small sample sizes and specific demographics of the participants also limit how well these findings apply to the broader public.
The long-term improvements seen in the patient group are also subject to external influences. The patients continued their usual clinical treatments, including other psychiatric medications, over the 12-month follow-up period. Natural changes in the course of their illness, new therapies, or major life events during that year could explain the sustained gains in quality of life.
“I would strongly caution against interpreting this study as evidence that a single dose of DMT produces benefits lasting for a year,” Araújo said. “Participants received DMT in a carefully controlled clinical environment together with psychological preparation, support during the experience, and integration afterward.”
“They also continued their usual clinical care, and many things can happen over a 12-month period,” Araújo said. “Because there was no placebo group, we cannot separate the pharmacological effects of DMT from psychological support, expectations, subsequent treatments, life events, or the natural course of depression.”
The researchers emphasized that these treatments require specialized protocols and safety measures. “Another important point is that these findings should not be interpreted as supporting unsupervised use of DMT,” Araújo said. “The intervention was conducted under medical and psychological supervision in accordance with clinical research protocols.”
Future placebo-controlled, double-blind studies with larger groups are needed to better understand the true therapeutic profile of inhaled DMT. The authors plan to expand their investigations to see if these initial patterns hold up under stricter experimental conditions.
“Our main priority now is to test inhaled DMT in larger and more rigorous controlled clinical trials,” Araújo said. “We are currently moving this research into a multicenter clinical study in patients with treatment-resistant depression.” A multicenter study involves conducting the trial at multiple clinics or hospitals to gather a larger and more diverse group of patients.
“Beyond determining whether the antidepressant effect can be replicated under controlled conditions, we are increasingly interested in understanding recovery more broadly, including quality of life, functioning, anxiety, suicidality, and other dimensions that matter to patients,” Araújo said. If successful, inhaled psychedelics could offer practical advantages for widespread clinical use.
“DMT is particularly interesting from a public health perspective because its psychedelic effects are very brief compared with substances such as psilocybin or ayahuasca,” Araújo said. “If its clinical efficacy is confirmed in larger controlled studies, this short duration could make psychedelic treatment considerably easier to integrate into health care systems.”
The focus on overall well-being represents a shifting paradigm in how medical professionals evaluate mental health treatments. “I think the broader point is that psychiatry should perhaps ask a larger question when evaluating new treatments: not only ‘Are the symptoms better?’ but also ‘Is the person living better?’” Araújo said.
“Depression affects relationships, work, physical functioning, hope, and the way people experience their own lives,” Araújo said. “For us, understanding whether psychedelic interventions can influence these dimensions is an important part of determining their actual clinical value.”
The study, “Beyond symptom reduction: DMT improves anxiety, life satisfaction, and quality of life in healthy volunteers and patients with depression,” was authored by Raynara Bolcont, Fernanda Palhano-Fontes, Handersson Barros, Sophie Laborde, Daniel Amorim, Marcelo Falchi-Carvalho, Nicole Galvão-Coelho, Isabel Wießner, and Draulio B. Araujo.
Leave a comment
You must be logged in to post a comment.